TheEdgeResearch
Home / Stocks / PBAX

Phoenix Biotech Acquisition Corp. (PBAX)

NASDAQ Financial Services Shell Companies
$5.85 ▲ +6.75%
Market Cap
$36.5M
Sector
Financial Services
Industry
Shell Companies
Beta
0.04
52-Wk Range
4.12-12.8
CEO
Christopher B. Ehrlich
Country
US
Currency
USD

Phoenix Biotech Acquisition Corp. operates in the Shell Companies industry of the Financial Services sector, headquartered in Oakland, CA, US. The stock last traded at $5.85, up 6.75% on the session, giving a market capitalisation of $36.5M. On trailing twelve-month figures it carries a trailing P/E of -0.07, a net margin of 0.0%. Its beta of 0.04 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.07
Price / Sales
0.00
Price / Book
-18.17
EV / EBITDA
-1.25
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
-0.06
Current ratio
0.14
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
IPO date
2021-11-30
Headquarters
Oakland, CA, US
About Phoenix Biotech Acquisition Corp.

Phoenix Biotech Acquisition Corp. currently lacks substantial business operations. The company's primary objective is to complete a strategic business combination, such as a merger, asset acquisition, share exchange, or other form of reorganization, with one or more suitable enterprises. Its focus is on identifying and integrating with a firm engaged in the healthcare or healthcare-related industries within the United States or Europe. This entity was established in 2021 and maintains its headquarters in Oakland, California.

Comparable companies

Phoenix Biotech Acquisition Corp. is most often compared with the following Financial Services names:

ASCAAVHIBSGACNTMGDNRIROHJTAIMACATGVC
More research on PBAX
PBAX technical analysis PBAX TheEdge Score Compare against peers
Open full interactive analysis & DCF →